Zobrazeno 91 - 100
of 197
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Patrick Maisonneuve, Roberto Gasparri, Domenico Galetta, Monica Casiraghi, Lorenzo Spaggiari, Filippo de Marinis, Cesare Gridelli, Rosalia Romano, Daniela Brambilla, Alberto Sandri, Francesco Petrella, Juliana Guarize
Publikováno v:
Clinical Lung Cancer. 20:97-106.e1
Background: Owing to the expected poor long-term outcomes and high postoperative morbidity and mortality, patients with stage IIIA-N2 tumors candidate to pneumonectomy (PN) are usually excluded from surgery. This study aims to analyze the outcome of
Autor:
Nicola Amedeo Mazzanti, Carolina Scauri, Simone Cusato, Chiara Vassallo, Bianca Domini, Chiara De Fino, Filippo de Marinis
Publikováno v:
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2019:228424031987789
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are established therapies for previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) EGFR-mutated patients. Osimertinib, a third-generation TKI, has recently
Publikováno v:
Lung Cancer Management. 2:493-504
SUMMARY Afatinib is an orally available irreversible blocker of the ErbB family of receptors, including the EGF receptor (EGFR). The EGFR mutations are detectable in 10–15% of western patients diagnosed with advanced non-small-cell lung cancer. In
Autor:
Cristiano Rampinelli, Eleonora Ancona, Filippo de Marinis, Gianluca Spitaleri, Alessia Pochesci, Antonio Passaro
Publikováno v:
American Journal of Respiratory and Critical Care Medicine. 196:1349-1350
Autor:
Paolo Bidoli, William J. John, Carla Visseren-Grul, Filippo de Marinis, Mircea Dediu, Symantha Melemed, Martin Reck, Olivier Molinier, Jesus Corral, Cesare Gridelli, Jean-Louis Pujol, Tarini Prasad Sahoo, Nadia Chouaki, Luis Paz-Ares, Eckart Laack, Mike Thomas, Annamaria Zimmermann
Publikováno v:
Journal of Clinical Oncology. 31:2895-2902
Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and upd
Autor:
Libero Giuffreda, Martin Wolf, Vittorio Gebbia, Silvia Marsoni, Salah-Eddin Al-Batran, Antonio Rossi, Marcello Tiseo, Laura Dal Zotto, Filippo de Marinis, Akin Atmaca, Chiara D’ Antonio
Publikováno v:
Journal of Thoracic Oncology. 8:1091-1094
Background: In vitro data suggest that panobinostat (LBH589), a pan-deacetylase inhibitor, may add therapeutic benefit in the treatment of small-cell lung cancer (SCLC) with regression of tumors. Methods: This multicenter, nonrandomized phase 2 trial
Autor:
Martin Reck, Thierry Pieters, Filippo de Marinis, Katherine B. Winfree, Jean-Louis Pujol, Julie Beyrer, Luis Paz-Ares, Nadia Chouaki, Bárbara Parente, William J. John, Cesare Gridelli, Anna Zimmermann, Gary Middleton, Jesus Corral, Symantha Melemed, Carla Visseren-Grul, Rodryg Ramlau
Publikováno v:
Journal of Thoracic Oncology. 7(11):1713-1721
IntroductionIn a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non–small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results.Metho
Autor:
Alessia Pochesci, Cristina Noberasco, Gianluca Spitaleri, Filippo de Marinis, Antonio Passaro, Ester Del Signore, Chiara Catania
Publikováno v:
Journal of thoracic disease. 8(3)
The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) changed dramatically the history of non-small cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Several randomized prospective trials confirmed th
Autor:
Giovanna Finocchiaro, Filippo de Marinis, Marcello Tiseo, Giulio Cerea, Alessandro Del Conte, Laura Giannetta, Maria Rita Migliorino, Rita Chiari, Marco Angelo Burgio, Francesca Mazzoni, Agnese Montanino, Alessandro Morabito, Federico Cappuzzo, Nicola Normanno, Roberta Buosi, Paolo Bidoli, Diego Cortinovis, Luisa Foltran, Silvia Ferrari
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 99
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR-tyrosine kinase inhibitors (TKI), most of them progress within 12 months fro
Autor:
Santiago Viteri, Peng Cao, Claudio Dazzi, Anastasios Gkountakos, Filippo de Marinis, Niki Karachaliou, Sara Pilotto, Mariacarmela Santarpia, Chiara Lazzari, Rafael Rosell, Daniela Morales-Espinosa, José Serrano, Imane Chaib, Alberto Verlicchi
Innovative therapeutic agents have significantly improved outcomes, with an acceptable safety profile, in a substantial proportion of non-small cell lung cancer (NSCLC) patients in whom the malignant phenotype of the disease is determined by oncogeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d81b1bf613f019a8c1cc45a49b2d9b2
http://hdl.handle.net/11562/974620
http://hdl.handle.net/11562/974620